Challenges in β 3 -adrenoceptor agonist drug development

Arch J.R. (2002) β₃-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol 440: 99–107.

Arch J.R. (2004) Do low-affinity states of β-adrenoceptors have roles in physiology and medicine? Br J Pharmacol 143: 517–518.

Arch J.R. (2008) The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: Perspectives from β₃-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 378: 225–240.

Arch J.R.S. (1989) The brown adipocyte β-adrenoceptor. Proc Nutr Soc 48: 215–223.

Arch J.R.S. (2011) Thermogenesis and related metabolic targets in anti-diabetic therapy. In: Schwanstecher M. . (ed.). Handbook of Experimental Pharmacology – Diabetes, Springer: Heidelberg, in press.

Arch J.R.S. Ainsworth A.T. Cawthorne M.A. Piercy V. Sennitt M.V. Thody V.E. (1984a) Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309: 163–165.

Arch J.R.S. Ainsworth A.T. Ellis R.D.M. Piercy V. Thody V.E. Thurlby P.L. (1984b) Treatment of obesity with thermogenic β-adrenoceptor agonists: Studies on BRL 26830A in rodents. Int J Obes 8(Suppl. 1): 1–11.

Arch J.R.S. Kaumann A.J. (1993) β₃ and atypical β-adrenoceptors. Med Res Rev 13: 663–729.

Bhadada S.V., Patel, B.M., Mehta, A.A. and Goyal R.K. (2011) β₃ receptors: role in cardiometabolic disorders. Ther Adv Endocrinol Metab. E-print 10.1177/2042018810390259.

Brahmadevara N. Shaw A.M. MacDonald A. (2003) Evidence against β₃-adrenoceptors or low affinity state of β₁-adrenoceptors mediating relaxation in rat isolated aorta. Br J Pharmacol 138: 99–106.

Brawley L. Shaw A.M. MacDonald A. (2000) β₁-, β₂- and atypical β-adrenoceptor-mediated relaxation in rat isolated aorta. Br J Pharmacol 129: 637–644.

Cohen M.L. Bloomquist W. Ito M. Lowell B.B. (2000) β₃ receptors mediate relaxation in stomach fundus whereas a fourth β receptor mediates tachycardia in atria from transgenic β₃ receptor knockout mice. Receptors Channels 7: 17–23.

Cypess A.M. Lehman S. Williams G. Tal I. Rodman D. Goldfine A.B. (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360: 1509–1517.

Darimont C. Turini M. Epitaux M. Zbinden I. Richelle M. Montell E. (2004) β3-adrenoceptor agonist prevents alterations of muscle diacylglycerol and adipose tissue phospholipids induced by a cafeteria diet. Nutr Metab (Lond) 1: 4–4.

Deng C. Paoloni-Giacobino A. Kuehne F. Boss O. Revelli J.-P. Moinat M. (1997) Respective degree of expression of β₁-, β₂- and β₃-adrenoceptors in human brown and white adipose tissues. Br J Pharmacol 118: 929–934.

Emorine L.J. Marullo S. Briend-Sutren M.M. Patey G. Tate K. Delavier-Klutchko C. (1989) Molecular characterization of the human β₃-adrenergic receptor. Science 245: 1118–1121.

Evans B.A. Papaioannou M. Hamilton S. Summers R.J. (1999) Alternative splicing generates two isoforms of the β₃-adrenoceptor which are differentially expressed in mouse tissues. Br J Pharmacol 127: 1525–1531.

Evans B.A. Sato M. Sarwar M. Hutchinson D.S. Summers R.J. (2010) Ligand-directed signalling at β-adrenoceptors. Br J Pharmacol 159: 1022–1038.

Feldmann H.M. Golozoubova V. Cannon B. Nedergaard J. (2009) UCP1 ablation induces obesity and abolishes diet-induced thermogenesis in mice exempt from thermal stress by living at thermoneutrality. Cell Metab 9: 203–209.

Furchgott R.F. . (1972) The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H. Muecholl E. . (eds). Catecholamines, Springer-Verlag: New York, 283–335..

Goble S.D. Wang L. Howell K.L. Bansal A. Berger R. Brockunier L. (2010) Heterocyclic acetamide and benzamide derivatives as potent and selective β₃-adrenergic receptor agonists with improved rodent pharmacokinetic profiles. Bioorg Med Chem Lett 20: 1895–1899.

Golozoubova V. Cannon B. Nedergaard J. (2006) UCP1 is essential for adaptive adrenergic nonshivering thermogenesis. Am J Physiol Endocrinol Metab 291: E350–E357.

Harms H.H. Zaagsma J. Van der Wal B. (1974) β-adrenoceptor studies. III. On the β-adrenoceptors in rat adipose tissue. Eur J Pharmacol 25: 87–91.

Heaton J.M. (1972) The distribution of brown adipose tissue in the human. J Anat 112: 35–39.

Holloway B.R. Howe R. Rao B.S. Stribling D. Mayers R.M. Briscoe M.G. (1991) ICI D7114 a novel selective β-adrenoceptor agonist selectively stimulates brown fat and increases whole-body oxygen consumption. Br J Pharmacol 104: 97–104.

Islam-Ali B. Khan S. Price S.A. Tisdale M.J. (2001) Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF). Br J Cancer 85: 758–763.

Kaumann A.J. (1989) Is there a third heart β-adrenoceptor? Trends Pharmacol Sci 10: 316–320.

Kaumann A.J. (1997) Four β-adrenoceptor subtypes in the mammalian heart. Trends Pharmacol Sci 18: 70–76.

Kaumann A.J. Engelhardt S. Hein L. Molenaar P. Lohse M. (2001) Abolition of (-)-CGP 12177-evoked cardiostimulation in double β₁/β₂-adrenoceptor knockout mice. Obligatory role of β₁-adrenoceptors for putative β₄-adrenoceptor pharmacology. Naunyn Schmiedebergs Arch Pharmacol 363: 87–93.

Kaumann A.J. Preitner F. Sarsero D. Molenaar P. Revelli J.P. Giacobino J.P. (1998) (-)-CGP 12177 causes cardiostimulation and binds to cardiac putative β₄-adrenoceptors in both wild-type and β₃-adrenoceptor knockout mice. Mol Pharmacol 53: 670–675.

Kennedy A. Martinez K. Chuang C.C. LaPoint K. McIntosh M. (2009) Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: Mechanisms of action and implications. J Nutr 139: 1–4.

Konkar A.A. Zhai Y. Granneman J.G. (2000) β₁-adrenergic receptors mediate β₃-adrenergic-independent effects of CGP 12177 in brown adipose tissue. Mol Pharmacol 57: 252–258.

Krief S. Lonnqvist F. Raimbault S. Baude B. Van Spronson A. Arner P. (1993) Tissue distribution of β₃-adrenergic receptor mRNA in man. J Clin Invest 91: 344–349.

Lafontan M. Berlan M. (1993) Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 34: 1057–1091.

Lean M.E. (1989) Brown adipose tissue in humans. Proc Nutr Soc 48: 243–256.

Liu X. Perusse F. Bukowiecki L.J. (1998) Mechanisms of the antidiabetic effects of the β₃-adrenergic agonist CL-316243 in obese Zucker-ZDF rats. Am J Physiol 274: R1212–R1219.

Meier M.K. Alig L. Burgi-Saville M.E. Muller M. (1984) Phenethanolamine derivatives with calorigenic and antidiabetic qualities. Int J Obesity 8(Suppl. 1): 215–225.

Nedergaard J. Bengtsson T. Cannon B. (2007) Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 293: E444–E452.

Rolli V. Radosavljevic M. Astier V. Macquin C. Castan-Laurell I. Visentin V. (2007) Lipolysis is altered in MHC class I zinc-α₂-glycoprotein deficient mice. FEBS Lett 581: 394–400.

Russell S.T. Hirai K. Tisdale M.J. (2002) Role of β₃-adrenergic receptors in the action of a tumour lipid mobilizing factor. Br J Cancer 86: 424–428.

Russell S.T. Tisdale M.J. (2010) Antidiabetic properties of zinc-α₂-glycoprotein in ob/ob mice. Endocrinology 151: 948–957.

Schenk S. Saberi M. Olefsky J.M. (2008) Insulin sensitivity: Modulation by nutrients and inflammation. J Clin Invest 118: 2992–3002.

Schiffelers S.L. Blaak E.E. Saris W.H. van Baak M.A. (2000) In vivo β₃-adrenergic stimulation of human thermogenesis and lipid use. Clin Pharmacol Ther 67: 558–566.

Schwartz E.A. Zhang W.Y. Karnik S.K. Borwege S. Anand V.R. Laine P.S. (2010) Nutrient modification of the innate immune response: A novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler Thromb Vasc Biol 30: 802–808.

Sennitt M.V. Arch J.R.S. Levy A.L. Simson D.L. Smith S.A. Cawthorne M.A. (1985) Anti-hyperglycaemic action of BRL 26830, a novel β-adrenoceptor agonist, in mice and rats. Biochem Pharmacol 34: 1279–1285.

Sennitt M.V. Kaumann A.J. Molenaar P. Beeley L.J. Young P.W. Kelly J. (1998) The contribution of classical (β_1/2-) and atypical β-adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel β₃-adrenoceptor agonists of differing selectivities. J Pharmacol Exp Ther 285: 1084–1095.

Stearns R.A. Miller R.R. Tang W. Kwei G.Y. Tang F.S. Mathvink R.J. (2002) The pharmacokinetics of a thiazole benzenesulfonamide β₃-adrenergic receptor agonist and its analogs in rats, dogs, and monkeys: Improving oral bioavailability. Drug Metab Dispos 30: 771–777.

Sugimoto T. Ogawa W. Kasuga M. Yokoyama Y. (2005) Chronic effects of AJ-9677 on energy expenditure and energy source utilization in rats. Eur J Pharmacol 519: 135–145.

Ursino M.G. Vasina V. Raschi E. Crema F. De Ponti F. (2009) The β₃-adrenoceptor as a therapeutic target: Current perspectives. Pharmacol Res 59: 221–234.

van Baak M.A. Hul G.B. Toubro S. Astrup A. Gottesdiener K.M. DeSmet M. (2002) Acute effect of L-796568, a novel β₃-adrenergic receptor agonist, on energy expenditure in obese men. Clin Pharmacol Ther 71: 272–279.

van Marken Lichtenbelt W.D. Vanhommerig J.W. Smulders N.M. Drossaerts J.M. Kemerink G.J. Bouvy N.D. (2009) Cold-activated brown adipose tissue in healthy men. N Engl J Med 360: 1500–1508.

Virtanen K.A. Rouru J. Hanninen V. Savontaus E. Rouvari T. Teirmaa T. (1997) Chronic treatment with BRL 35135 potentiates the action of insulin on lipid metabolism. Eur J Pharmacol 332: 215–218.

Watanabe M. Houten S.M. Mataki C. Christoffolete M.A. Kim B.W. Sato H. (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484–489.

Wilson S. Arch J.R. Thurlby P.L. (1984) Genetically obese C57BL/6 ob/ob mice respond normally to sympathomimetic compounds. Life Sci 35: 1301–1309.

Wilson S. Thurlby P.L. Arch J.R. (1987) Substrate supply for thermogenesis induced by the β-adrenoceptor agonist BRL 26830A. Can J Physiol Pharmacol 65: 113–119.

Yen T.T. McKee M.M. Stamm N.B. (1984) Thermogenesis and weight control. Int J Obesity 8(Suppl. 1): 65–78.